# Open Cann > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/open-cann/ > **Published:** 2026-09-07T12:26:56-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:22-04:00 > **Clinical Summary:** Explore the neuroprotective properties of CBD from a systematic review, highlighting its potential in treating neurological conditions. --- ✦ New CED Clinical Relevance #65 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. NeurologyCBDResearchMental HealthPolicySafetyPain Why This Matters This article matters for clinicians and their patients as it provides a comprehensive review of recent clinical trials on CBD’s neuroprotective properties from 2020 to 2024, which could potentially expand the therapeutic applications of cannabis in neurological disorders. Understanding these findings can aid clinicians in making informed decisions about CBD use for their patients with neurodegenerative conditions or brain injuries. Clinical Summary In the review spanning 2020-2024, CBD derived from Cannabis sativa L. demonstrated notable neuroprotective effects in various clinical trials. These findings suggest potential therapeutic applications for CBD in managing neurological disorders, which could significantly impact patient care and warrant further investigation for its integration into clinical practice. Dr. Caplan’s Take “In light of the latest research on CBD’s neuroprotective potential from clinical trials between 2020 and 2024, it’s clear that Cannabis sativa L. holds promising therapeutic possibilities for neurological conditions. However, as a responsible physician, I emphasize the need for further human-based studies to confirm these findings and ensure safe, effective applications in clinical practice.” – Dr. Benjamin Caplan, MD Clinical Perspective 🔬 In the context of evolving research, the systematic review titled “CBD and Neuroprotection” (2020-2024) highlights potential neuroprotective benefits of Cannabis sativa L., primarily CBD. While these findings are promising, it’s crucial to acknowledge the complexity in interpreting results due to variability in dosage, delivery methods, and patient populations across trials. Confounders such as interactions with other medications and individual susceptibilities may also influence outcomes. In clinical practice, these findings could inspire further exploration of CBD as a potential adjunct therapy for neurodegenerative conditions, but more rigorous studies are needed to confirm its efficacy and safety in this context. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Open%20Cann%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90869)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90869)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Open%20Cann%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D90869)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Project Twenty21 Australia finds year-long improvements in pain and anxiety](https://cedclinic.com/project-twenty21-australia-finds-year-long-improvements-in-pain-and-anxiety/) - [Marijuana Improves Symptoms For People With Anorexia And Other Eating Disorders, Study Finds](https://cedclinic.com/marijuana-improves-symptoms-for-people-with-anorexia-and-other-eating-disorders-study-finds/) - [Au Nebraska, la Cour suprême valide définitivement les lois sur le cannabis médical](https://cedclinic.com/au-nebraska-la-cour-supreme-valide-definitivement-les-lois-sur-le-cannabis-medical/) 📰 Source: [https://open-cann.com/](https://open-cann.com/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).